Literature DB >> 4074601

Influence of rifampicin and isoniazid on the kinetics of phenytoin.

L Kay, J P Kampmann, T L Svendsen, B Vergman, J E Hansen, L Skovsted, M Kristensen.   

Abstract

Clearance of phenytoin after i.v. injection of 100 mg was studied in six patients before and after 2 weeks daily treatment with 450 mg rifampicin, and in 14 patients with tuberculosis receiving standard treatment with 450 mg rifampicin, 300 mg isoniazid, and 1200 mg ethambutol daily. Acetylator status was measured by urinary acetylated sulphadimidine. Clearance of phenytoin in patients receiving only rifampicin increased from 46.7 ml min-1 +/- 20.6 ml min-1 to 97.8 ml min-1 +/- 33.4 ml min-1 (P less than 0.01), while clearance in patients on three drugs increased from 47.1 +/- 23.4 ml min-1 to 81.3 ml min-1 +/- 41.6 ml min-1 (P less than 0.01). No significant differences were observed between the six fast acetylators and the eight slow acetylators. Phenytoin kinetics were unchanged after further 3 months of combined treatment. Rifampicin is a strong inducer of the elimination of phenytoin. Combined treatment with isoniazid has no counter-acting effect in either fast or slow acetylators.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4074601      PMCID: PMC1400889          DOI: 10.1111/j.1365-2125.1985.tb05071.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

2.  Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

3.  Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.

Authors:  B Lumholtz; K Siersbaek-Nielsen; L Skovsted; J Kampmann; J M Hansen
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

4.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

5.  [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].

Authors:  U Peters; T U Hausamen; F Grosse-Brockhoff
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

6.  Letter: Rifampicin and drug metabolism.

Authors:  E K Syvälahti; K K Pihlajamäki; E J Iisalo
Journal:  Lancet       Date:  1974-07-27       Impact factor: 79.321

7.  Interaction of sodium warfarin and rifampin. Studies in man.

Authors:  R A O'Reilly
Journal:  Ann Intern Med       Date:  1974-09       Impact factor: 25.391

8.  Diphenylhydantoin intoxication. A complication of isoniazid therapy.

Authors:  H Kutt; R Brennan; H Dehejia; K Verebely
Journal:  Am Rev Respir Dis       Date:  1970-03

9.  Induction of the unspecific microsomal hydroxylase in the human liver.

Authors:  H Remmer; B Schoene; R A Fleischmann
Journal:  Drug Metab Dispos       Date:  1973 Jan-Feb       Impact factor: 3.922

10.  Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.

Authors:  D D Breimer; W Zilly; E Richter
Journal:  Clin Pharmacol Ther       Date:  1977-04       Impact factor: 6.875

View more
  25 in total

1.  Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.

Authors:  Kwee Poo Yeo; Stephen L Lowe; Ming Tung Lim; James R Voelker; Jennifer L Burkey; Stephen D Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 2.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

Review 3.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

Review 4.  Pharmacokinetic drug interactions with phenytoin (Part II).

Authors:  R L Nation; A M Evans; R W Milne
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

5.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 6.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

8.  Phenytoin interaction with rifampicin.

Authors:  F J Abajo
Journal:  BMJ       Date:  1988-10-22

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Neurological manifestations and toxicities of the antituberculosis drugs. A review.

Authors:  M R Holdiness
Journal:  Med Toxicol       Date:  1987 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.